Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Cim Investment Management Inc.

Cim Investment Management Inc. lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,123 shares of the company’s stock after selling 266 shares during the quarter. Cim Investment Management Inc.’s holdings in Medpace were worth $463,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mackenzie Financial Corp purchased a new stake in Medpace during the second quarter worth approximately $747,000. The Manufacturers Life Insurance Company raised its stake in shares of Medpace by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,129 shares of the company’s stock valued at $8,702,000 after acquiring an additional 94 shares during the period. Mcmorgan & Co. LLC lifted its holdings in shares of Medpace by 3.9% during the 2nd quarter. Mcmorgan & Co. LLC now owns 9,555 shares of the company’s stock valued at $3,935,000 after acquiring an additional 358 shares in the last quarter. AQR Capital Management LLC boosted its position in Medpace by 62.3% during the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock worth $127,941,000 after purchasing an additional 119,257 shares during the period. Finally, AXA S.A. increased its holdings in Medpace by 11.4% in the 2nd quarter. AXA S.A. now owns 34,018 shares of the company’s stock valued at $14,010,000 after purchasing an additional 3,479 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Up 1.6 %

Shares of NASDAQ:MEDP opened at $331.44 on Friday. Medpace Holdings, Inc. has a 12-month low of $227.21 and a 12-month high of $459.77. The firm has a market cap of $10.27 billion, a PE ratio of 33.79, a price-to-earnings-growth ratio of 1.88 and a beta of 1.35. The company has a fifty day simple moving average of $370.19 and a 200 day simple moving average of $390.19.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business had revenue of $528.10 million for the quarter, compared to analyst estimates of $528.41 million. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.93 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of a number of recent research reports. Guggenheim reduced their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $420.00 to $350.00 in a research report on Friday. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the company from $415.00 to $345.00 in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research note on Wednesday, July 24th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Medpace currently has an average rating of “Moderate Buy” and a consensus price target of $395.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.